Efficacy of Palifermin in the Treatment of Oral Mucositis in Non-hematopoietic Stem Cell Transplant Pediatric Patients: Experience of a Single Tertiary Hospital

Overview

Journal J Egypt Natl Canc Inst

Specialty Oncology

Date 2024 Dec 1

PMID 39617846

Authors

Hasna Hamzi

Amal Binhassan

Amal Najmeldin

Ebtsam Alhariri

Bodour Elhussein

Nour Althibani

Ahmad Alenazi

Shahad Alsharif

Mohammad Alshahrani

Omar Alsharif

Nawaf Alkhayat

Yasser Elborai

Affiliations

Soon will be listed here.

Abstract

Background: Severe oral mucositis (OM) is one of the adverse events post-chemotherapy, radiation, and stem cell transplantation with major clinical and economic impact. The management of severe OM remains challenging. This study aimed to look for the benefit and clinical impact of palifermin for mucositis among the non-transplanted pediatric cancer population.

Methods: This is a descriptive retrospective study extended from 2016 to 2020 at Prince Sultan Military Medical City (PSMMC), in Saudi Arabia. During this period all pediatric patients (< 14 years of age) on chemotherapy and complicated by severe OM that required palifermin (35 courses), as off-labeled medication, were analyzed looking for the clinical demographics, primary diagnosis, chemotherapy agents used, effectiveness, and tolerability of palifermin.

Results: A total of 29 patients with severe OM received 35 palifermin courses. All of them received 60 mcg/kg/day IV for 3 consecutive days. 20% of them have acute lymphoblastic leukemia (ALL). We noticed that 60% of severe OM required palifermin post anthracycline while high-dose methotrexate aggravates the risk in 40% of them. Only 25.7% of the patients required TPN for a median duration of 5 days and 54.3% of them received opioids for a median duration of 4 days. Twenty patients (57.1%) had used antibiotics, 4 patients were on antifungal medication and 1 patient was on anti-viral medication concomitant with antibiotics.

Conclusion: Palifermin is safe and well tolerated and shows some effect in non-hematopoietic stem cell transplant pediatric patients with severe oral mucositis post-intensified chemotherapy or radiation therapy.

References

Shetty S, Maruthi M, Dhara V, de Arruda J, Abreu L, Mesquita R . Oral mucositis: Current knowledge and future directions. Dis Mon. 2021; 68(5):101300. DOI: 10.1016/j.disamonth.2021.101300. View

Barkokebas A, Silva I, de Andrade S, Carvalho A, Alcino Monteiro Gueiros L, Martins Paiva S . Impact of oral mucositis on oral-health-related quality of life of patients diagnosed with cancer. J Oral Pathol Med. 2014; 44(9):746-51. DOI: 10.1111/jop.12282. View

Lalla R, Sonis S, Peterson D . Management of oral mucositis in patients who have cancer. Dent Clin North Am. 2007; 52(1):61-77, viii. PMC: 2266835. DOI: 10.1016/j.cden.2007.10.002. View

Naidu M, Ramana G, Rani P, Krishna Mohan I, Suman A, Roy P . Chemotherapy-induced and/or radiation therapy-induced oral mucositis--complicating the treatment of cancer. Neoplasia. 2004; 6(5):423-31. PMC: 1531648. DOI: 10.1593/neo.04169. View

Morris J, Rudebeck M, Neudorf S, Moore T, Duerst R, Shah A . Safety, Pharmacokinetics, and Efficacy of Palifermin in Children and Adolescents with Acute Leukemias Undergoing Myeloablative Therapy and Allogeneic Hematopoietic Stem Cell Transplantation: A Pediatric Blood and Marrow Transplant Consortium Trial. Biol Blood Marrow Transplant. 2016; 22(7):1247-1256. DOI: 10.1016/j.bbmt.2016.02.016. View

Liu D, Seyboth B, Mathew S, Gilheeney S, Chou A, Drill E . Retrospective Evaluation of Palifermin Use in Nonhematopoietic Stem Cell Transplant Pediatric Patients. J Pediatr Hematol Oncol. 2017; 39(4):e177-e182. DOI: 10.1097/MPH.0000000000000791. View

Vera-Llonch M, Oster G, Ford C, Lu J, Sonis S . Oral mucositis and outcomes of allogeneic hematopoietic stem-cell transplantation in patients with hematologic malignancies. Support Care Cancer. 2006; 15(5):491-6. DOI: 10.1007/s00520-006-0176-9. View

Carneiro-Neto J, de-Menezes J, Moura L, Massucato E, de-Andrade C . Protocols for management of oral complications of chemotherapy and/or radiotherapy for oral cancer: Systematic review and meta-analysis current. Med Oral Patol Oral Cir Bucal. 2016; 22(1):e15-e23. PMC: 5217492. DOI: 10.4317/medoral.21314. View

McGuire D, Fulton J, Park J, Brown C, Correa M, Eilers J . Systematic review of basic oral care for the management of oral mucositis in cancer patients. Support Care Cancer. 2013; 21(11):3165-77. DOI: 10.1007/s00520-013-1942-0. View

10.

Saito H, Watanabe Y, Sato K, Ikawa H, Yoshida Y, Katakura A . Effects of professional oral health care on reducing the risk of chemotherapy-induced oral mucositis. Support Care Cancer. 2014; 22(11):2935-40. PMC: 4183888. DOI: 10.1007/s00520-014-2282-4. View

11.

Mercadante S, Aielli F, Adile C, Ferrera P, Valle A, Fusco F . Prevalence of oral mucositis, dry mouth, and dysphagia in advanced cancer patients. Support Care Cancer. 2015; 23(11):3249-55. DOI: 10.1007/s00520-015-2720-y. View

12.

Rivers C, Iovoli A, Chatterjee U, Hermann G, Singh A . Intravenous fluids for pain management in head and neck cancer patients undergoing chemoradiation. Ann Transl Med. 2021; 9(10):912. PMC: 8184454. DOI: 10.21037/atm-20-3910. View

13.

Epstein J, Silverman Jr S, Paggiarino D, Crockett S, Schubert M, Senzer N . Benzydamine HCl for prophylaxis of radiation-induced oral mucositis: results from a multicenter, randomized, double-blind, placebo-controlled clinical trial. Cancer. 2001; 92(4):875-85. DOI: 10.1002/1097-0142(20010815)92:4<875::aid-cncr1396>3.0.co;2-1. View

14.

McKeown S, Hyland P, Locke M, Mackenzie I, Irwin C . Keratinocyte growth factor and scatter factor expression by regionally defined oral fibroblasts. Eur J Oral Sci. 2003; 111(1):42-50. DOI: 10.1034/j.1600-0722.2003.00002.x. View

15.

Spielberger R, Stiff P, Bensinger W, Gentile T, Weisdorf D, Kewalramani T . Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med. 2004; 351(25):2590-8. DOI: 10.1056/NEJMoa040125. View

16.

Lucchese A, Matarese G, Huanca Ghislanzoni L, Gastaldi G, Manuelli M, Gherlone E . Efficacy and effects of palifermin for the treatment of oral mucositis in patients affected by acute lymphoblastic leukemia. Leuk Lymphoma. 2015; 57(4):820-7. DOI: 10.3109/10428194.2015.1081192. View

17.

Bowen J, Al-Dasooqi N, Bossi P, Wardill H, Van Sebille Y, Al-Azri A . The pathogenesis of mucositis: updated perspectives and emerging targets. Support Care Cancer. 2019; 27(10):4023-4033. DOI: 10.1007/s00520-019-04893-z. View

18.

Czyzewski K, Debski R, Krenska A, Wysocki M, Styczynski J . Palifermin in children undergoing autologous stem cell transplantation: a matched-pair analysis. Anticancer Res. 2014; 34(12):7379-82. View

19.

Lauritano D, Petruzzi M, Di Stasio D, Lucchese A . Clinical effectiveness of palifermin in prevention and treatment of oral mucositis in children with acute lymphoblastic leukaemia: a case-control study. Int J Oral Sci. 2013; 6(1):27-30. PMC: 3967308. DOI: 10.1038/ijos.2013.93. View